# The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes

> **NCT02762708** · PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 12 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus
- Obesity

## Interventions

- **PROCEDURE:** Roux-en-Y Gastric Bypass (RYGB)
- **BEHAVIORAL:** Caloric Restriction
- **DRUG:** Exendin-9,39
- **DRUG:** Normal Saline

## Key facts

- **NCT ID:** NCT02762708
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-03
- **Primary completion:** 2018-01-06
- **Final completion:** 2018-01-06
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2022-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02762708

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02762708, "The Effect of Bariatric Surgery on Metabolism, the Metabolome and Microbiome in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02762708. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*